Comparison of circulating total sFLT-1 to placental-specific sFLT-1 e15a in women with suspected preeclampsia.

[1]  A. Ohkuchi,et al.  Economic evaluation of the sFlt-1/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study , 2021, Hypertension Research.

[2]  Sean-Tee J. M. Lim,et al.  Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. , 2020, Obstetrics and gynecology.

[3]  P. Seed,et al.  Placental growth factor measurements in the assessment of women with suspected Preeclampsia: A stratified analysis of the PARROT trial. , 2020, Pregnancy hypertension.

[4]  N. Cheung,et al.  Urinary and Serum Angiogenic Markers in Women With Preexisting Diabetes During Pregnancy and Their Role in Preeclampsia Prediction , 2019, Diabetes Care.

[5]  O. Lapaire,et al.  sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective , 2019, Disease markers.

[6]  D. Rolnik,et al.  Stability of placental growth factor, soluble fms-like tyrosine kinase 1, and soluble fms-like tyrosine kinase 1 e15a in human serum and plasma. , 2019, Placenta.

[7]  B. Mol,et al.  Prediction of pre‐eclampsia: review of reviews , 2019, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[8]  A. Khalil,et al.  Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial , 2019, The Lancet.

[9]  S. Kane,et al.  Midpregnancy prediction of pre-eclampsia using serum biomarkers sFlt-1 and PlGF. , 2019, Pregnancy hypertension.

[10]  S. Brennecke,et al.  Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study , 2018, BMC Pregnancy and Childbirth.

[11]  M. Hund,et al.  Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany , 2018, BMC Health Services Research.

[12]  E. Cordioli,et al.  Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals. , 2018, Pregnancy hypertension.

[13]  J. Galaz,et al.  Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[14]  I. Cetin,et al.  Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[15]  G. Frampton,et al.  Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. , 2016, Health technology assessment.

[16]  M. Vatish,et al.  sFlt‐1/PlGF ratio test for pre‐eclampsia: an economic assessment for the UK , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[17]  M. Rousseau,et al.  Sflt-1 in heart failure: relation with disease severity and biomarkers , 2016, Scandinavian journal of clinical and laboratory investigation.

[18]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[19]  A. Shub,et al.  Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity , 2015, Hypertension.

[20]  B. Wang,et al.  Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice , 2015, PloS one.

[21]  B. Wang,et al.  In Vivo Experiments Reveal the Good, the Bad and the Ugly Faces of sFlt-1 in Pregnancy , 2014, PloS one.

[22]  L. Magee,et al.  The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. , 2014, Pregnancy hypertension.

[23]  C. Roberts,et al.  First trimester screening of serum soluble fms-like tyrosine kinase-1 and placental growth factor predicting hypertensive disorders of pregnancy. , 2013, Pregnancy hypertension.

[24]  D. McIntire,et al.  Endothelial microparticles and the antiangiogenic state in preeclampsia and the postpartum period. , 2012, American journal of obstetrics and gynecology.

[25]  K. Joseph,et al.  Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[26]  J. V. D. van der Post,et al.  Expression of Placental FLT1 Transcript Variants Relates to Both Gestational Hypertensive Disease and Fetal Growth , 2011, Hypertension.

[27]  J. Hutcheon,et al.  Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model , 2011, The Lancet.

[28]  K. Palmer.  Assessing the Circulating Placental-Specific Anti-angiogenic Protein sFLT-1 e15a in Preeclampsia. , 2018, Methods in molecular biology.